AlphAIalphai — Financial news for AI agents
tradingview.comSEP 13 min read$CRL

Is This the Right Time to Add CRL Stock to Your Portfolio?

Charles River Laboratories (CRL) is well-positioned for growth due to strong research-model demand and portfolio streamlining. The company's DSA segment shows improving demand, bookings, and backlog. CRL stock has surged 79% over the past year, outperforming its industry and the S&P 500. The company has a market cap of $13.92 billion and an earnings yield of 3.9%. However, mixed demand trends and NHP-related cost volatility remain risks. The Zacks Consensus Estimate for CRL’s 2026 earnings has i

Original reporting
tradingview.com
Published Sep 1, 2026, 2:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 1, 2026, 4:55 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Is This the Right Time to Add CRL Stock to Your Portfolio? — source image
Source · tradingview.com
Decision brief

The 30-second read

$CRLBullishMed
01

Why it matters

The Q2 2026 earnings release provides the first public view of the company's latest performance, highlighting modest DSA growth and a strong backlog, which may influence investor positioning.

02

Market read

Fresh earnings data for a mid‑cap biotech services firm; could drive short‑term price action and inform sector outlook.

03

What to watch

Potential integration risk from the recent Cambodia acquisition and lingering supply‑chain issues for NHPs.

Relevance 8/10Novelty 8/10Timing: Q2 2026 earnings release

Background

Charles River Laboratories (CRL) is a leading non‑clinical drug development services provider with a market cap of ~$13.9B.

Company-level read

Ticker impact

$CRLBullishHigh confidence
Context

Q2 2026 earnings report shows DSA revenue up 0.2%, net bookings $701M and backlog $1.97B, indicating modest growth.

Expected impact

Potential upside of 5‑8% over the next 2‑4 weeks if the market digests the improved bookings.

Evidence & confidence

The earnings beat and rising backlog are fresh data; investors typically reward such signals in a mid‑cap biotech services stock.

Market effects

Sector

Positive earnings may lift the broader contract research organization (CRO) sector as peers are seen to benefit from similar demand trends.

Regional

U.S. biotech services stocks could see modest gains; European CROs may face relative pressure.

Global

The data reinforce a gradual recovery in non‑clinical research spending worldwide.

Counterpoint

What could challenge this read

NHP cost volatility and uneven demand recovery could pressure margins, suggesting a more cautious stance.

Key entities

  • company
    Charles River Laboratories International, Inc.

    Subject of the earnings report.

Read at source← All news

Related articles

AUG 21
$ACBHighAI 8/10

Aurora Snipes Back At Curaleaf’s Hostile Bid

Aurora Cannabis rejected Curaleaf's hostile $4 per share bid, urging shareholders to take no action. Curaleaf claims its offer represents a 45% premium over Aurora's 30-day average share price. Aurora's shares rose 34% to $3.89, while Curaleaf's OTC shares gained 6% to $9.80. Aurora's board formed a special committee to review the offer, which expires on December 1.

yahoo.com2 min
AUG 19
$AMLXHighAI 8/10

Biotech Stocks At 52-Week Highs - AMLX +63% With Phase 3 Data, VOGX +25%, OBIO +19%, ATRC, CRL

Several biotech stocks hit 52-week highs on August 18, 2026. Amylyx (AMLX) surged 63% to $35.39 after positive Phase 3 data and a $350M share offering. Vogenx (VOGX) rose 25% to $20.01 post-IPO. AtriCure (ATRC) reached $46.33 with 12.8% revenue growth. Charles River (CRL) hit $289.60 despite a 2.7% revenue dip. Orchestra BioMed (OBIO) climbed 19% to $5.77 with FDA breakthrough designations.

rttnews.com3 min
AUG 14
$CRLMed

Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript

Charles River Laboratories (CRL) reported Q2 2026 results, citing a strengthening biopharmaceutical demand environment. DSA net book-to-bill rose to nearly 1.2x for a third straight quarter above 1x. Organic revenue growth returned to 0.1%. Operating margin improved 420 bps sequentially to 20.5% after divestitures. CRL also announced collaborations with Eli Lilly (TuneLab) and Arovella Therapeutics (NGS).

yahoo.com6 min
AUG 9
$CRLMed

Charles River Laboratories International (CRL) Cuts Guidance, Is It Still Undervalued?

Charles River Laboratories International (CRL) cut its 2026 GAAP earnings guidance and reported a quarterly net loss, citing divestiture-related charges and slightly lower revenue year over year. The article notes strong recent share performance and presents two valuation views, including a $313.61 fair value versus a $267.49 last close, plus a planned $510M acquisition of K.F. (Cambodia) Ltd.

simplywall.st6 min